The influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm

European Journal of Vascular and Endovascular Surgery

Volumn 23, Issue 5, 2002, Pages 421-425

  Jones, K ^a   Powell, J ^a,c   Brown, L ^a   Greenhalgh, R ^a   Jormsjo S ^b   Eriksson, P ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Aortic aneurysm; Fibrinolysis; Gene; Plasminogen activator inhibitor 1; Survival

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; CREATININE;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANEURYSM SURGERY; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ECHOGRAPHY; ELECTIVE SURGERY; FEMALE; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROMOTER REGION; SURGICAL RISK; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM; VASCULAR SURGERY;

AGED; AORTIC ANEURYSM, ABDOMINAL; CREATININE; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENOTYPE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 0036582227     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1633     Document Type: Article

References (24)

1. BENGTSSON H, NORRGARD O, ANGUIST KA et al. Ultrasonographic screening of the abdominal aorta among siblings of patients with abdominal aortic aneurysms. Br J Surg 1989; 76: 589-591.
2. BAIRD PA, SADNOVIK AD, YEE IML et al. Sibling risks of abdominal aortic aneurysm. Lancet 1995; 346: 601-604.
3. MCKUSICK VA. The defect in Marfan syndrome. Nature 1991; 352: 279-281.
4. SUPERTI-FUERGA A, STEINMANN B, RAMIREZ F, BYERS PM. Molecular defects of type III procollagen in Ehlers Danlos syndrome type IV. Human Genet 1989; 82: 104-108
5. POWELL JT, BASHIR A, DAWSON S et al. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm. Clin Sci 1990; 78: 13-16.
6. ST JEAN PL, ZHANG XC, HART BK et al. Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann Hum Genet 1995; 59: 17-24.
7. JONES KG, BRULL DJ, BROWN LC et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysm. Circulation 2001; 103: 2260-2265.
8. MARIAN AJ. On genetics, inflammation and abdominal aortic aneurysm. Circulation 2001; 103: 2222-2224.
9. CARMELIET P, MOONS L, LIJNEN R et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-444.
10. ALLAIRE E, HASENSTAB D, KENAGY RD et al. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 1998; 98: 249-255.
11. ROSSAAK JI, VAN RIJ AM, JONES GT, HARRIS EG. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysm. J Vasc Surg 2000; 31: 1026-1032
12. ERIKSSON P, KALLIN B, VAN'T HOOFT FM, BAVENHOLM P. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U.S.A. 1995; 92: 1851-1855.
13. The U.K. Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998; 352: 1649-1655.
14. BRADY AR, FOWKES FGR, GREENHALGH RM et al. Risk factors for postoperative death following elective surgical repair of abdominal aortic aneurysm: results from the U.K. Small Aneurysm Trial. Br J Surg 2000; 87: 742-749.
15. MENGES T, HERMANS PWM, LITTLE S et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357: 1096-1097.
16. JEAN-CLAUDE J, NEWMAN KM, LI H, GREGORY AK, TILSON MD. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery 1994; 116: 472-478.
17. REILLY JM, SICARD GA, LUCORE CL. Abnormal expression of plasminogen activators in aortic aneurysmal occlusive disease. J Vasc Surg 1994; 19: 865-872.
18. LOUWRENS HD, KWAAN HC, PEARCE WH, YAO JS, VERRUSIO S. Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Eur J Vasc Endovasc Surg 1995; 10: 289-293.
19. SCHNEIDERMAN J, BORDIN GM, ENGELBERG I et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 1995; 96: 639-645.
20. DAWSON SJ, WIMAN B, HAMSTEN A et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
21. YOON S, TROMP G, VONGPUNSAWAD S et al. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun 1999; 265: 563-568.
22. FOON AH, GREVE JW, VAN DER LINDEN CJ, BUURMAN WA. Increased concentrations of cytokines abd adhesion molecules in patients after repair of abdominal aortic aneurysm. Eur J Surg 1996; 162: 287-296.
23. THOMPSON MM, NASIM A, SAYERS RD et al. Oxygen free radical and cytokine generation during endovascular and conventional aneurysm repair. Eur J Vasc Endovasc Surg 1996; 12: 70-75.
24. ADAM DJ, LUDLAM CJ, RUCKLEY CV, BRADBURY AW. Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms. J Vasc Surg 1999; 30: 641-650.